AIM ImmunoTech (AIM) vs Curanex Pharmaceuticals (CURX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Curanex Pharmaceuticals is the larger company by market cap ($7.2 million vs $7.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AIM | CURX |
|---|---|---|
| Share price | $0.1809 | $4.61 |
| Market cap | $7.22M | $7.23M |
| 1-day change | -0.22% | -3.15% |
| EPS (TTM) | $-2.98 | $-7.80 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.79 | $16.94 |
| 52-week low | $0.17 | $3.58 |
| Distance from 52-week high | -93.52% | -72.79% |
| Analyst consensus | none | — |
| Avg. price target upside | +2249.36% | — |
| Average volume | 4.70M | 19.85K |
| Shares outstanding | 39.89M | 1.57M |
| Employees | 19 | 6 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About AIM ImmunoTech
AIM stock →AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 19 employees
About Curanex Pharmaceuticals
CURX stock →Curanex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients with inflammatory diseases. It develops Phyto-N for various therapeutic areas, including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
AIM vs CURX FAQ
Which is bigger, AIM ImmunoTech or Curanex Pharmaceuticals?
Curanex Pharmaceuticals (CURX) is larger, with a market capitalization of $7.23M compared with $7.22M for AIM ImmunoTech (AIM).
Are AIM ImmunoTech and Curanex Pharmaceuticals in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for AIM ImmunoTech and Biotechnology: Pharmaceutical Preparations for Curanex Pharmaceuticals.